Kosicki, Michael https://orcid.org/0000-0001-7173-8852
Laboy CintrĂ³n, Dianne
Keukeleire, Pia https://orcid.org/0000-0002-8828-636X
Schubach, Max https://orcid.org/0000-0002-2032-6679
Page, Nicholas F.
Georgakopoulos-Soares, Ilias https://orcid.org/0000-0003-3641-1488
Akiyama, Jennifer A. https://orcid.org/0000-0002-0667-9355
Plajzer-Frick, Ingrid
Novak, Catherine S.
Kato, Momoe
Hunter, Riana D.
von Maydell, Kianna
Barton, Sarah
Godfrey, Patrick
Beckman, Erik
Sanders, Stephan J. https://orcid.org/0000-0001-9112-5148
Kircher, Martin
Pennacchio, Len A. https://orcid.org/0000-0002-8748-3732
Ahituv, Nadav https://orcid.org/0000-0002-7434-8144
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (UM1HG009408, UM1HG011966)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (U01MH116438, R01MH109907)
Article History
Received: 16 April 2024
Accepted: 13 May 2025
First Online: 23 May 2025
Competing interests
: N.A. is a cofounder and on the scientific advisory board of Regel Therapeutics. N.A. received funding from BioMarin Pharmaceutical Incorporate. Remaining authors declare no competing interests.